Ophthalmology

Anti-VEGF and pan-retinal photocoagulation can be effective, but neither are "one-and-done" therapies. Physicians must be proactive about how they handle patients with PDR.

A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.

While DEX implants improved BCVA in patients with DME, new data shows the improvement diminished over time.

New data has shown that using the anti-VEGF agent in patients with AMD that are older than 85 does not increase their risk of heart attack or stroke.

While some baseline characteristics may put patients at a greater risk of developing macular atrophy, ultimately, ranibizumab was not determined to raise that risk.

The device was able to accurately identify the presence, or lack thereof, of more-than-mild DR at least 87% of the time.

The contact lenses, which darken when exposed to strong UV light, were cleared through the 501(k) pathway.

Researchers found no evidence that adding targeted retinal photocoagulation to ranibizumab treatment improved visual outcomes, decreased treatment burden, or reduced demand for anti-VEGF therapy

A stem cell-based implant has been shown in a phase 1/2a trial to not only halt AMD disease progression but possibly improve vision.

A novel subretinal implantation of a stem cell-based bioengineered patch may restore vision or prevent further vision loss.

Although popular, organic light-emitting sleep masks have been reported to be ineffective in reducing disease progression for patients with diabetic macular edema.

This week on MDNN: America trends toward healthier outcomes, the first-ever gene therapy procedure was performed, and President Donald Trump declared his stance on opioid traffickers.

According to the investigators, this is the first time a consistent and dramatic global effect on antisense transcription has been associated with a disease state in humans.

With the approval, the syringe becomes the first with anti-VEGF agent approved by the FDA for use to treat DR and DME.

This is the first and only FDA-approved gene therapy for treatment for an inherited disease.

The anti-VEGF marketed as EYLEA has new phase 3 study results in its ongoing trial for NPDR consideration.

Foveomacular, juxta-macular, and peripheral retina punch biopsies can be used to determine protein levels and identify patterns of expression.

While not the preferred solution, choroidal neovascularization removal in patients with AMD can be useful in specific circumstances.

According to data, patients with neovascular AMD can continue their prescribed use of AP/AC medication without negative effects on AMD outcomes.

The market price for gene therapy greatly exceed the costs of the gene editing development and the equipment required for the task.

For treating AMD, the 3 anti-VEGF agents report similar efficacy and safety results in trials but different molecular structure and biochemical properties.

The fall of 2017 brought the approval of new gene therapies, and could usher in a new area of personalized medicine.

Long-term use of nonsteroidal anti-inflammatories may decrease the risk of developing age-related macular degeneration.

Less invasive interventions could be achieved in AMD with encapsulated microspheres as a method of delivering treatment to patients.

There is some promising evidence for the use of microperimetry in functionally assessing AMD, despite research results being limited.